GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (NAS:ADAP) » Definitions » Shiller PE Ratio

Adaptimmune Therapeutics (Adaptimmune Therapeutics) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Adaptimmune Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Adaptimmune Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptimmune Therapeutics Shiller PE Ratio Chart

Adaptimmune Therapeutics Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Adaptimmune Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Adaptimmune Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Adaptimmune Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptimmune Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's Shiller PE Ratio falls into.



Adaptimmune Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Adaptimmune Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Adaptimmune Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.18/130.0000*130.0000
=-0.180

Current CPI (Dec. 2023) = 130.0000.

Adaptimmune Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201306 0.000 98.000 0.000
201312 0.000 99.200 0.000
201406 1.489 99.800 1.940
201409 -0.008 100.000 -0.010
201412 -0.004 99.900 -0.005
201506 -0.300 100.100 -0.390
201509 -0.018 100.200 -0.023
201512 -0.282 100.400 -0.365
201603 -0.240 100.400 -0.311
201606 -0.300 101.000 -0.386
201609 -0.240 101.500 -0.307
201612 -0.240 102.200 -0.305
201703 -0.300 102.700 -0.380
201706 -0.240 103.500 -0.301
201709 -0.009 104.300 -0.011
201712 -0.300 105.000 -0.371
201803 -0.240 105.100 -0.297
201806 -0.480 105.900 -0.589
201809 0.060 106.600 0.073
201812 -0.360 107.100 -0.437
201903 -0.240 107.000 -0.292
201906 -0.420 107.900 -0.506
201909 -0.360 108.400 -0.432
201912 -0.300 108.500 -0.359
202003 -0.240 108.600 -0.287
202006 -0.240 108.800 -0.287
202009 -0.240 109.200 -0.286
202012 -0.240 109.400 -0.285
202103 -0.240 109.700 -0.284
202106 -0.240 111.400 -0.280
202109 -0.300 112.400 -0.347
202112 -0.240 114.700 -0.272
202203 -0.300 116.500 -0.335
202206 -0.300 120.500 -0.324
202209 -0.240 122.300 -0.255
202212 -0.180 125.300 -0.187
202303 0.006 126.800 0.006
202306 -0.120 129.400 -0.121
202309 -0.180 130.100 -0.180
202312 -0.180 130.000 -0.180

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Adaptimmune Therapeutics  (NAS:ADAP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Adaptimmune Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptimmune Therapeutics (Adaptimmune Therapeutics) Business Description

Traded in Other Exchanges
Address
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, non-small cell lung cancer, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.
Executives
Elliot Norry officer: Chief Medical Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Bertrand William C Jr officer: Chief Operating Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
John Lunger officer: Chief Patient Supply Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Adrian Rawcliffe officer: Chief Financial Officer 440 SOUTH BROAD STREET, UNIT 1906, PHILADELPHIA PA 19146
Kristen Hege director 500 FORBES BLVD, SOUTH SAN FRANCISCO CA 94070
Garry E Menzel director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Priti Hegde director TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Andrew R Allen director 2525 28TH STREET, SUITE 200, BOULDER CO 80301
Cintia Piccina officer: Chief Commercial Officer 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Gavin Wood officer: Chief Financial Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Joanna Elizabeth Brewer officer: Chief Scientific Officer 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Helena Katrina Tayton-martin officer: Chief Operating Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Lawrence M Alleva director 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James Noble director, officer: Chief Executive Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX

Adaptimmune Therapeutics (Adaptimmune Therapeutics) Headlines

From GuruFocus